Thrombospondin-1 and Pigmented Epithelium Derived Factor Levels in Patients With Diabetes Mellitus.

Overview

You are being asked to be in a research study to determine blood levels and vitreous levels of compounds called thrombospondin 1 (TSP1) and pigment epithelium derived factor (PEDF). These compounds exists naturally in your body.

Full Title of Study: “Modulation of Thrombospondin-1 and Pigment Epithelium Derived Factor Levels in Vitreous Fluid and Plasma of Patients With Diabetes”

Study Type

  • Study Type: Observational
  • Study Design
    • Time Perspective: Prospective
  • Study Primary Completion Date: March 2014

Detailed Description

The hypothesis tested here is that diabetic patients that express the higher molecular weight pigment epithelium-derived factor (PEDF) isoform have lower thrombospondin-1 (TSP1) level and, as a result, are at a greater risk for the development of more severe diabetic retinopathy.

Interventions

  • Biological: Blood draw
    • 3-4 tablespoons of blood will be drawn, one time.

Arms, Groups and Cohorts

  • Blood draw
    • Blood (approximately equal to 3 to 4 tablespoons) will be drawn at the Wills Eye Institute, 1 time.

Clinical Trial Outcome Measures

Primary Measures

  • Level of thrombospondin (TSP1) and pigment epithelium derived factor (PEDF) in the vitreous and plasma
    • Time Frame: up to 6 months
    • Your voluntary participation in this study may help determine how different TSP1 and PEDF levels correlate with diabetic eye disease.

Participating in This Clinical Trial

Inclusion Criteria

  • Ability to provide written informed consent and comply with study assessments for the full duration of the study – Diabetes Mellitus – Undergoing pars plana vitrectomy for any reason Exclusion Criteria:

  • Use of any anti-VEGF (vascular endothelial growth factor ) medications

Gender Eligibility: All

Minimum Age: 18 Minutes

Maximum Age: N/A

Are Healthy Volunteers Accepted: No

Investigator Details

  • Lead Sponsor
    • MidAtlantic Retina
  • Provider of Information About this Clinical Study
    • Sponsor-Investigator: MidAtlantic Retina, Principal Investigator – Wills Eye
  • Overall Official(s)
    • Marc Spirn, M.D., Principal Investigator,

Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.

At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.